Larimar Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 2.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.70M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.